Patents by Inventor John Blenis

John Blenis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P13K-MTORC1-S6K1 signaling pathway biomarkers predictive of anti-cancer responses
    Patent number: 11366100
    Abstract: The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: June 21, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Thomas M. Roberts, Haoxuan Tong, Jean Zhao, John Blenis
  • P13K-MTORC1-S6K1 SIGNALING PATHWAY BIOMARKERS PREDICTIVE OF ANTI-CANCER RESPONSES
    Publication number: 20170184565
    Abstract: The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.
    Type: Application
    Filed: February 12, 2015
    Publication date: June 29, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Thomas M. Roberts, Haoxuan Tong, Jean Zhao, John Blenis
  • TARGETING MTOR SUBSTRATES IN TREATING PROLIFERATIVE DISEASES
    Publication number: 20130252950
    Abstract: Provided are over 300 mTOR kinase targets identified by a comprehensive phosphoproteomics assay. Methods of targeting mTOR kinase targets, methods to determine the level of mTOR activity by measuring the level of phosphorylation of an mTOR targeted phosphorylation site, methods for distinguishing different classes of mTOR activity in a cell based on phosphoproteomic analysis of mTOR-targeted proteins are also provided. Also provided is the classification of a hyperproliferative disease based on phosphoproteomic analysis of mTOR-targeted proteins, as well as the personalization of therapeutic methods for the treatment of hyperproliferative disease based on phosphoproteomics. Also provided are therapeutic methods including administering to a subject an mTOR inhibitor, an mTOR inhibitor and an additional kinase inhibitor, or a dual inhibitor of mTOR and an additional kinase based on the phosphorylation levels of mTOR targets determined in the subject.
    Type: Application
    Filed: September 23, 2011
    Publication date: September 26, 2013
    Applicant: President and Fellows of Harvard College
    Inventors: John Blenis, Steven P. Gygi, Yonghao Yu
  • P54s6k and p85s6k genes, proteins, primers, probes, and detection methods
    Patent number: 6372467
    Abstract: Disclosed are novel mammalian kinases, p54S6K and p85S6K. Also disclosed are methods for identifying compounds that modulate, or which are modulated by, p54S6K or p85S6K. In addition, the invention discloses methods for diagnosing or treating a cellular proliferative disease.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: April 16, 2002
    Assignee: President and Fellows of Harvard College
    Inventors: John Blenis, Kay K. Lee-Fruman, Calvin J. Kuo